Search hospitals > Washington > Seattle
CCOP - Virginia Mason Research Center
Claim this profileSeattle, Washington 98101
Global Leader in Breast Cancer
Global Leader in Type 1 Diabetes
Conducts research for Diabetes
Conducts research for Lung Cancer
Conducts research for Cancer
210 reported clinical trials
5 medical researchers
Summary
CCOP - Virginia Mason Research Center is a medical facility located in Seattle, Washington. This center is recognized for care of Breast Cancer, Type 1 Diabetes, Diabetes, Lung Cancer, Cancer and other specialties. CCOP - Virginia Mason Research Center is involved with conducting 210 clinical trials across 184 conditions. There are 5 research doctors associated with this hospital, such as Huong T. Pham, David Aboulafia, MD, Sandra Lord, MD, and Carla Greenbaum, MD.Area of expertise
1Breast Cancer
Global LeaderER positive
Stage IV
ER negative
2Type 1 Diabetes
Global LeadermIAA positive
IA-2A positive
ICA positive
Top PIs
Huong T. PhamVirginia Mason Medical Center2 years of reported clinical research
Studies Tumors
Studies Lung Cancer
19 reported clinical trials
47 drugs studied
David Aboulafia, MDVirginia Mason Medical Center8 years of reported clinical research
Studies Lymphoma
Studies Sarcoma
11 reported clinical trials
26 drugs studied
Sandra Lord, MDBenaroya Research Institute1 year of reported clinical research
Studies Type 1 Diabetes
Studies Diabetes
6 reported clinical trials
10 drugs studied
Carla Greenbaum, MDBenaroya Research Institute3 years of reported clinical research
Studies Type 1 Diabetes
Studies Diabetes
4 reported clinical trials
4 drugs studied
Clinical Trials running at CCOP - Virginia Mason Research Center
Type 1 Diabetes
Cancer
Ulcerative Colitis
Hodgkin's Lymphoma
Colorectal Cancer
Adenomatous Polyposis
Diabetes
Inflammatory Bowel Disease
Ulcer
Lymphoma
Frexalimab + Insulin
for Type 1 Diabetes
This is a randomized, parallel group, double-blind Phase 2 study that consists of 2 parts. In Part A the safety of the highest dose-level of frexalimab in adults (age range 18-35 y.o.) will be established. In Part B, a dose-finding study (adolescents and young adults, 12-21 y.o.) evaluating the safety and efficacy of 3 age-adjusted dose-levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. The purpose of this study is to determine safety and efficacy of different dose-levels of frexalimab, by assessment of preservation of endogenous insulin secretion in participants with newly diagnosed T1D aged 12 to 21 years compared with placebo on top of standard insulin therapy, and to determine the dose-response relationship and minimal efficacious dose in Part B. Study details include: - Screening period: at least 3 weeks and up to 5 weeks (Up to 11 days may be required to get investigational medicinal product [IMP] on site. Enrollment date of the participant must take into consideration this constraint.) - Double-blind treatment period (104 weeks): -- Main treatment period: 52 weeks -- Blinded extension: 52 weeks - Safety follow-up: 26 weeks (not applicable for participants entering the open-label study) The treatment duration will be up to 104 weeks, the total study duration will be up to 135 weeks.
Recruiting0 awards Phase 27 criteria
JAK Inhibitors
for Type 1 Diabetes
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Recruiting0 awards Phase 213 criteria
Rituximab + Abatacept
for Type 1 Diabetes
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.
Recruiting0 awards Phase 220 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CCOP - Virginia Mason Research Center?
CCOP - Virginia Mason Research Center is a medical facility located in Seattle, Washington. This center is recognized for care of Breast Cancer, Type 1 Diabetes, Diabetes, Lung Cancer, Cancer and other specialties. CCOP - Virginia Mason Research Center is involved with conducting 210 clinical trials across 184 conditions. There are 5 research doctors associated with this hospital, such as Huong T. Pham, David Aboulafia, MD, Sandra Lord, MD, and Carla Greenbaum, MD.